Ask AI
ProCE Banner Activity

Live Workshop Series—Immune Checkpoint Inhibitors in BCC and CSCC: Aligning Clinical Practice With Best Practices and Guidelines

Slideset

Downloadable slides on the role and utility of immune checkpoint inhibitor therapy for patients with BCC and CSCC and the optimal management of immune-related adverse events associated with immune checkpoint inhibitors.

Released: June 16, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity is intended for oncologists, dermatologists, advanced practice providers, nurses, pharmacists, and other HCPs who care for patients with basal cell carcinoma and cutaneous squamous cell carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate patients with BCC and CSCC on the risks and benefits of immune checkpoint inhibitor therapy

  • Integrate immune checkpoint inhibitors into treatment plans for appropriate patients with BCC and CSCC, considering clinical data and expert recommendations along with patient goals and perspectives

  • Evaluate the potential clinical impact of novel intralesional and perioperative immune checkpoint inhibitor therapies under investigation for patients with BCC and CSCC

  • Manage immune-related adverse events promptly in patients with BCC and CSCC who are receiving immune checkpoint inhibitor therapy